Edition:
United Kingdom

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

7.52USD
20 Apr 2018
Change (% chg)

$-0.02 (-0.27%)
Prev Close
$7.54
Open
$7.54
Day's High
$7.65
Day's Low
$7.32
Volume
242,622
Avg. Vol
238,634
52-wk High
$14.45
52-wk Low
$5.02

Chart for

About

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of... (more)

Overall

Beta: --
Market Cap(Mil.): $377.79
Shares Outstanding(Mil.): 33.23
Dividend: --
Yield (%): --

Financials

  BLCM.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -2.94 -- --
ROI: -56.99 1.58 14.38
ROE: -67.22 2.41 16.07

BRIEF-Bellicum Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* BELLICUM PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

18 Apr 2018

BRIEF-Bellicum Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* BELLICUM PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

16 Apr 2018

BRIEF-Bellicum Announces Clinical Hold Lifted On U.S. Studies Of BPX-501

* BELLICUM ANNOUNCES CLINICAL HOLD LIFTED ON U.S. STUDIES OF BPX-501

11 Apr 2018

BRIEF-Bellicum Pharmaceuticals Reports Qtrly Loss Per Share $0.66

* BELLICUM PHARMACEUTICALS PROVIDES OPERATIONAL UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017

13 Mar 2018

BRIEF-Bellicum Announces Interim Results Showing Low Rates Of Cancer Recurrence In Pediatric AML Patients Treated With BPX-501

* BELLICUM ANNOUNCES INTERIM RESULTS SHOWING LOW RATES OF CANCER RECURRENCE IN PEDIATRIC AML PATIENTS TREATED WITH BPX-501

13 Mar 2018

BRIEF-Bellicum Pharma Says Effective Feb 20, Board Approved Increase In Size Of Board To 8 Members

* BELLICUM PHARMA SAYS EFFECTIVE FEB 20, BOARD APPROVED INCREASE IN SIZE OF BOARD TO 8 MEMBERS - SEC FILING Source text: (http://bit.ly/2BMB6hN) Further company coverage:

23 Feb 2018

BRIEF-Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies

* BELLICUM ANNOUNCES UPDATE ON CLINICAL HOLD OF U.S. BPX-501 STUDIES

23 Feb 2018

Bellicum's cancer drug trials on clinical hold, shares tumble

Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the company's experimental cancer drug after three cases of brain disease linked to head trauma.

30 Jan 2018

Bellicum's cancer drug trials on clinical hold, shares tumble

Jan 30 Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the company's experimental cancer drug after three cases of brain disease linked to head trauma.

30 Jan 2018

BRIEF-Bellicum Pharmaceuticals Announces Clinical Hold On BPX-501 Clinical Trials In U.S.

* BELLICUM PHARMACEUTICALS ANNOUNCES CLINICAL HOLD ON BPX-501 CLINICAL TRIALS IN THE UNITED STATES

30 Jan 2018

Earnings vs. Estimates